ÌÇÐÄÆƽâ°æ

AstraZeneca is a global biopharmaceutical company with several leading pharmaceutical products. In 2025, AstraZeneca’s top pharmaceutical product by revenue was **, a medication used to treat type 2 diabetes mellitus. In the same year, Tagrisso, a cancer drug, generated around *** billion U.S. dollars in revenue for the company.

AstraZeneca company profile

AstraZeneca is a global pharmaceutical company with many employees all over the world. As of 2024, the highest proportion of AstraZeneca’s employees was based in Europe. The global office and corporate headquarters of AstraZeneca are located in Cambridge, UK. In 2025, emerging markets and the U.S. market accounted for the highest revenues for AstraZeneca. The company is also a global leader in pharmaceutical research and development. 

AstraZeneca’s R&D

AstraZeneca has many research and development programs that are focused on several therapeutic areas, like oncology, cardiovascular, renal and metabolic diseases, and respiratory disease. AstraZeneca’s research and development expenditures have increased recently. In 2025, over ** percent of AstraZeneca’s total revenue was spent on research and development. As of 2024, AstraZeneca was among the world’s top pharmaceutical companies according to the number of drugs it had under development at that time.